Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …

Background Omalizumab is a non-steroidal medication indicated for the treatment of poorly
controlled moderate-to-severe allergic asthmatics. This observational study examines the …

Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of …

Randomized clinical trials (RCTs) are the gold standard for the assessment of any
therapeutic intervention. Real-life (RL) studies are needed to verify the provided results …

Controlled clinical trials have shown the recombinant humanized monoclonal anti-IgE
antibody omalizumab to improve asthma control and reduce symptom exacerbations in …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …